# A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

> **NCT03537651** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 130 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT03537651
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-25
- **Primary completion:** 2020-10-28
- **Final completion:** 2023-09-29
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03537651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03537651, "A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03537651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*